

ACIP Japanese Encephalitis (JE) and Yellow Fever (YF) Vaccines Work Group

Joseph A. Bocchini Jr., MD

ACIP Work Group Chair

Professor and Chairman

Department of Pediatrics

Louisiana State University Health Sciences Center

Shreveport, LA

February 26, 2015



JE and YF Vaccines Work Group Members

ACIP members

Joseph Bocchini (Chair)

Lorry Rubin

Liaison representatives

Elizabeth Barnett (AAP)

Cody Meissner (AAP)

Robert Schechter (AIM)

Ex Officio members

Doran Fink (FDA)

Jesse Geibe (DoD)

Michael Holbrook (NIH)

Lewis Markoff (FDA)

Pat Repik (NIH)

CDC Leads

Erin Staples (NCEZID/DVBD)

Marc Fischer (NCEZID/DVBD)

Invited consultants

Alan Barrett

Lin Chen

Myron Levin

John Roehrig

Mary Wilson

Overview of Key Issues

- ❑ **In April 2013, WHO Strategic Advisory Group of Experts (SAGE) concluded single dose of YF vaccine is sufficient to confer lifelong protection**
 - **Booster doses are not needed**
 - **Additional data needed to identify specific risk groups which might benefit from second dose or booster dose**

- ❑ **Since 1965, International Health Regulations (IHR) allow countries to require YF vaccine dose within past 10 years for entry**
 - **In June 2014, WHO World Health Assembly adopted an amendment to IHR that extends YF vaccine protection to the life of the person vaccinated**
 - **Change to IHR will take effect in June 2016**

ACIP JE and YF Vaccines Work Group Activities

- ❑ Reformed JE Vaccine Work Group to include YF vaccine in October 2013
- ❑ Met 15 times to discuss YF vaccine booster doses
 - Reviewed epidemiology of YF in travelers
 - Reviewed duration of immunity following YF vaccine and safety of YF vaccine booster doses
 - Performed GRADE analysis
 - Developed and revise proposed recommendations
- ❑ Three previous presentations to ACIP on this topic
 - October 2013: Work group charge and plans
 - February 2014: YF and YF vaccine background information
 - June 2014: GRADE and initial recommendations presented

Summary of June 2014 Meeting

- ❑ Overall, general support to remove booster dose requirement for most travelers
- ❑ Questions raised about groups for whom additional doses would be considered
 - Immune response in children
 - Interval between doses in certain groups
 - What constitutes high-risk settings

Focus of Recent Work Group Activities

- ❑ **Work Group members presented to AAP Committee on Infectious Diseases in November 2014**
 - Presented updated analysis on immune response of children to YF vaccine
 - Discussed whether children's immune response to YF vaccine was different from adults
- ❑ **Work Group discussed time interval for additional doses in pregnant women, hematopoietic stem cell transplant recipients, and HIV-infected individuals**
- ❑ **Work Group further clarified high-risk settings for exposure to wild-type YF virus**

Today's YF Vaccine Session

- ❑ **Summary of GRADE, consideration of special populations, and proposed recommendations for YF vaccine booster dose**
 - **J. Erin Staples, MD, PhD, NCEZID, CDC**
- ❑ **Discussion**
- ❑ **Vote**